Hepatocellular alterations and dysregulation of oncogenic pathways in the liver of transgenic mice overexpressing growth hormone

References

• Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol 2010; 6:515 - 25; http://dx.doi.org/10.1038/nrendo.2010.123; PMID: 20664532
   PubMed Web of Science ®Google Scholar
• Lichanska AM, Waters MJ. How growth hormone controls growth, obesity and sexual dimorphism. Trends Genet 2008; 24:41 - 7; http://dx.doi.org/10.1016/j.tig.2007.10.006; PMID: 18063438
   PubMed Web of Science ®Google Scholar
• Xu J, Messina JL. Crosstalk between growth hormone and insulin signaling. Vitam Horm 2009; 80:125 - 53; http://dx.doi.org/10.1016/S0083-6729(08)00606-7; PMID: 19251037
   PubMed Web of Science ®Google Scholar
• Jansson JO, Ekberg S, Hoath SB, Beamer WG, Frohman LA. Growth hormone enhances hepatic epidermal growth factor receptor concentration in mice. J Clin Invest 1988; 82:1871 - 6; http://dx.doi.org/10.1172/JCI113804; PMID: 3264288
   PubMed Web of Science ®Google Scholar
• Ekberg S, Carlsson L, Carlsson B, Billig H, Jansson JO. Plasma growth hormone pattern regulates epidermal growth factor (EGF) receptor messenger ribonucleic acid levels and EGF binding in the rat liver. Endocrinology 1989; 125:2158 - 66; http://dx.doi.org/10.1210/endo-125-4-2158; PMID: 2791983
   PubMed Web of Science ®Google Scholar
• Miquet JG, González L, Matos MN, Hansen CE, Louis A, Bartke A, et al. Transgenic mice overexpressing GH exhibit hepatic upregulation of GH-signaling mediators involved in cell proliferation. J Endocrinol 2008; 198:317 - 30; http://dx.doi.org/10.1677/JOE-08-0002; PMID: 18480380
   PubMed Web of Science ®Google Scholar
• Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer?. Clin Endocrinol (Oxf) 2006; 64:115 - 21; http://dx.doi.org/10.1111/j.1365-2265.2005.02404.x; PMID: 16430706
   PubMed Web of Science ®Google Scholar
• Perry JK, Emerald BS, Mertani HC, Lobie PE. The oncogenic potential of growth hormone. Growth Horm IGF Res 2006; 16:277 - 89; http://dx.doi.org/10.1016/j.ghir.2006.09.006; PMID: 17101287
   PubMed Web of Science ®Google Scholar
• McGrane MM, Yun JS, Moorman AFM, Lamers WH, Hendrick GK, Arafah BM, et al. Metabolic effects of developmental, tissue-, and cell-specific expression of a chimeric phosphoenolpyruvate carboxykinase (GTP)/bovine growth hormone gene in transgenic mice. J Biol Chem 1990; 265:22371 - 9; PMID: 1702419
   PubMed Web of Science ®Google Scholar
• Kopchick JJ, Bellush LL, Coschigano KT. Transgenic models of growth hormone action. Annu Rev Nutr 1999; 19:437 - 61; http://dx.doi.org/10.1146/annurev.nutr.19.1.437; PMID: 10448532
   PubMed Web of Science ®Google Scholar
• Bartke A. Can growth hormone (GH) accelerate aging? Evidence from GH-transgenic mice. Neuroendocrinology 2003; 78:210 - 6; http://dx.doi.org/10.1159/000073704; PMID: 14583653
   PubMed Web of Science ®Google Scholar
• Wanke R, Hermanns W, Folger S, Wolf E, Brem G. Accelerated growth and visceral lesions in transgenic mice expressing foreign genes of the growth hormone family: an overview. Pediatr Nephrol 1991; 5:513 - 21; http://dx.doi.org/10.1007/BF01453693; PMID: 1911131
   PubMed Web of Science ®Google Scholar
• Orian JM, Lee CS, Weiss LM, Brandon MR. The expression of a metallothionein-ovine growth hormone fusion gene in transgenic mice does not impair fertility but results in pathological lesions in the liver. Endocrinology 1989; 124:455 - 63; http://dx.doi.org/10.1210/endo-124-1-455; PMID: 2642419
   PubMed Web of Science ®Google Scholar
• Orian JM, Tamakoshi K, Mackay IR, Brandon MR. New murine model for hepatocellular carcinoma: transgenic mice expressing metallothionein-ovine growth hormone fusion gene. J Natl Cancer Inst 1990; 82:393 - 8; http://dx.doi.org/10.1093/jnci/82.5.393; PMID: 2154583
   PubMed Web of Science ®Google Scholar
• Quaife CJ, Mathews LS, Pinkert CA, Hammer RE, Brinster RL, Palmiter RD. Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology 1989; 124:40 - 8; http://dx.doi.org/10.1210/endo-124-1-40; PMID: 2642417
   PubMed Web of Science ®Google Scholar
• Snibson KJ, Bhathal PS, Hardy CL, Brandon MR, Adams TE. High, persistent hepatocellular proliferation and apoptosis precede hepatocarcinogenesis in growth hormone transgenic mice. Liver 1999; 19:242 - 52; http://dx.doi.org/10.1111/j.1478-3231.1999.tb00042.x; PMID: 10395045
   PubMedGoogle Scholar
• Snibson KJ. Hepatocellular kinetics and the expression of growth hormone (GH) in the livers and liver tumours of GH-transgenic mice. Tissue Cell 2002; 34:88 - 97; http://dx.doi.org/10.1016/S0040-8166(02)00012-5; PMID: 12165243
   PubMed Web of Science ®Google Scholar
• Hoeflich A, Nedbal S, Blum WF, Erhard M, Lahm H, Brem G, et al. Growth inhibition in giant growth hormone transgenic mice by overexpression of insulin-like growth factor-binding protein-2. Endocrinology 2001; 142:1889 - 98; http://dx.doi.org/10.1210/en.142.5.1889; PMID: 11316754
   PubMed Web of Science ®Google Scholar
• Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003; 3:573 - 88; http://dx.doi.org/10.2174/1566524033479546; PMID: 14527088
   PubMed Web of Science ®Google Scholar
• Teoh NC. Proliferative drive and liver carcinogenesis: too much of a good thing?. J Gastroenterol Hepatol 2009; 24:1817 - 25; http://dx.doi.org/10.1111/j.1440-1746.2009.06121.x; PMID: 20002941
   PubMed Web of Science ®Google Scholar
• Snibson KJ, Bhathal PS, Adams TE. Overexpressed growth hormone (GH) synergistically promotes carcinogen-initiated liver tumour growth by promoting cellular proliferation in emerging hepatocellular neoplasms in female and male GH-transgenic mice. Liver 2001; 21:149 - 58; http://dx.doi.org/10.1034/j.1600-0676.2001.021002149.x; PMID: 11318985
   PubMedGoogle Scholar
• Vergani G, Mayerhofer A, Bartke A. Acute effects of human growth hormone on liver cells in vitro: a comparison with livers of mice transgenic for human growth hormone. Tissue Cell 1991; 23:607 - 12; http://dx.doi.org/10.1016/0040-8166(91)90017-N; PMID: 1776152
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48:1312 - 27; http://dx.doi.org/10.1002/hep.22506; PMID: 18821591
   PubMed Web of Science ®Google Scholar
• Spangenberg HC, Thimme R, Blum HE. Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009; 6:423 - 32; http://dx.doi.org/10.1038/nrgastro.2009.86; PMID: 19488072
   PubMed Web of Science ®Google Scholar
• Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010; 52:921 - 9; http://dx.doi.org/10.1016/j.jhep.2009.12.034; PMID: 20385424
   PubMed Web of Science ®Google Scholar
• Rogers AB, Theve EJ, Feng Y, Fry RC, Taghizadeh K, Clapp KM, et al. Hepatocellular carcinoma associated with liver-gender disruption in male mice. Cancer Res 2007; 67:11536 - 46; http://dx.doi.org/10.1158/0008-5472.CAN-07-1479; PMID: 18089782
   PubMed Web of Science ®Google Scholar
• Ruggieri A, Barbati C, Malorni W. Cellular and molecular mechanisms involved in hepatocellular carcinoma gender disparity. Int J Cancer 2010; 127:499 - 504; http://dx.doi.org/10.1002/ijc.25298; PMID: 20201099
   PubMed Web of Science ®Google Scholar
• Popow A, Nowak D, Malicka-Błaszkiewicz M. Actin cytoskeleton and beta-actin expression in correlation with higher invasiveness of selected hepatoma Morris 5123 cells. J Physiol Pharmacol 2006; 57:Suppl 7 111 - 23; PMID: 17228099
   PubMedGoogle Scholar
• Miller LM, Menthena A, Chatterjee C, Verdier-Pinard P, Novikoff PM, Horwitz SB, et al. Increased levels of a unique post-translationally modified betaIVb-tubulin isotype in liver cancer. Biochemistry 2008; 47:7572 - 82; http://dx.doi.org/10.1021/bi8005225; PMID: 18570381
   PubMed Web of Science ®Google Scholar
• Miquet JG, Sotelo AI, Bartke A, Turyn D. Suppression of growth hormone (GH) Janus tyrosine kinase 2/signal transducer and activator of transcription 5 signaling pathway in transgenic mice overexpressing bovine GH. Endocrinology 2004; 145:2824 - 32; http://dx.doi.org/10.1210/en.2003-1498; PMID: 15016718
   PubMed Web of Science ®Google Scholar
• Sotelo AI, Miquet JG, González L, Bartke A, Turyn D. Vitamin D3 cannot revert desensitization of growth hormone (GH)-induced STAT5-signaling in GH-overexpressing mice non-calcemic tissues. Growth Horm IGF Res 2008; 18:148 - 56; http://dx.doi.org/10.1016/j.ghir.2007.08.001; PMID: 17881271
   PubMed Web of Science ®Google Scholar
• Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007; 32:577 - 95; http://dx.doi.org/10.1007/s11064-006-9128-5; PMID: 16944320
   PubMed Web of Science ®Google Scholar
• Jacobs KM, Bhave SR, Ferraro DJ, Jaboin JJ, Hallahan DE, Thotala D. GSK-3β: A Bifunctional Role in Cell Death Pathways. Int J Cell Biol 2012; 2012:930710; http://dx.doi.org/10.1155/2012/930710; PMID: 22675363
   PubMedGoogle Scholar
• Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14:381 - 95; http://dx.doi.org/10.1016/S0898-6568(01)00271-6; PMID: 11882383
   PubMed Web of Science ®Google Scholar
• Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 2008; 20:581 - 9; http://dx.doi.org/10.1016/j.cellsig.2007.10.018; PMID: 18023328
   PubMed Web of Science ®Google Scholar
• Luedde T, Schwabe RFNF. NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8:108 - 18; http://dx.doi.org/10.1038/nrgastro.2010.213; PMID: 21293511
   PubMed Web of Science ®Google Scholar
• Schmid JA, Birbach A. IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor Rev 2008; 19:157 - 65; http://dx.doi.org/10.1016/j.cytogfr.2008.01.006; PMID: 18308615
   PubMed Web of Science ®Google Scholar
• Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9:59 - 71; http://dx.doi.org/10.1111/j.1582-4934.2005.tb00337.x; PMID: 15784165
   PubMed Web of Science ®Google Scholar
• Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002; 21:2593 - 604; http://dx.doi.org/10.1038/sj.onc.1205434; PMID: 11971194
   PubMed Web of Science ®Google Scholar
• Yuen MF, Wu PC, Lai VC, Lau JY, Lai CL. Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. Cancer 2001; 91:106 - 12; http://dx.doi.org/10.1002/1097-0142(20010101)91:1<106::AID-CNCR14>3.0.CO;2-2; PMID: 11148566
   PubMed Web of Science ®Google Scholar
• Stamatakos M, Palla V, Karaiskos I, Xiromeritis K, Alexiou I, Pateras I, et al. Cell cyclins: triggering elements of cancer or not?. World J Surg Oncol 2010; 8:111; http://dx.doi.org/10.1186/1477-7819-8-111; PMID: 21176227
   PubMed Web of Science ®Google Scholar
• Baik M, Yu JH, Hennighausen L. Growth hormone-STAT5 regulation of growth, hepatocellular carcinoma, and liver metabolism. Ann N Y Acad Sci 2011; 1229:29 - 37; http://dx.doi.org/10.1111/j.1749-6632.2011.06100.x; PMID: 21793836
   PubMed Web of Science ®Google Scholar
• Waxman DJ, O’Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol 2006; 20:2613 - 29; http://dx.doi.org/10.1210/me.2006-0007; PMID: 16543404
   PubMed Web of Science ®Google Scholar
• Zhang Y, Laz EV, Waxman DJ. Dynamic, sex-differential STAT5 and BCL6 binding to sex-biased, growth hormone-regulated genes in adult mouse liver. Mol Cell Biol 2012; 32:880 - 96; http://dx.doi.org/10.1128/MCB.06312-11; PMID: 22158971
   PubMed Web of Science ®Google Scholar
• Tannenbaum GS, Choi HK, Gurd W, Waxman DJ. Temporal relationship between the sexually dimorphic spontaneous GH secretory profiles and hepatic STAT5 activity. Endocrinology 2001; 142:4599 - 606; http://dx.doi.org/10.1210/en.142.11.4599; PMID: 11606424
   PubMed Web of Science ®Google Scholar
• MacLeod JN, Pampori NA, Shapiro BH. Sex differences in the ultradian pattern of plasma growth hormone concentrations in mice. J Endocrinol 1991; 131:395 - 9; http://dx.doi.org/10.1677/joe.0.1310395; PMID: 1783886
   PubMed Web of Science ®Google Scholar
• Sueyoshi T, Yokomori N, Korach KS, Negishi M. Developmental action of estrogen receptor-alpha feminizes the growth hormone-Stat5b pathway and expression of Cyp2a4 and Cyp2d9 genes in mouse liver. Mol Pharmacol 1999; 56:473 - 7; PMID: 10462534
   PubMed Web of Science ®Google Scholar
• Martinez CS, Piazza VG, Ratner LD, Matos MN, González L, Rulli SB, et al. Growth hormone STAT5-mediated signaling and its modulation in mice liver during the growth period. Growth Horm IGF Res 2013; 23:19 - 28; http://dx.doi.org/10.1016/j.ghir.2012.11.002; PMID: 23245546
   PubMed Web of Science ®Google Scholar
• Miquet JG, Muñoz MC, Giani JF, González L, Dominici FP, Bartke A, et al. Ames dwarf (Prop1(df)/Prop1(df)) mice display increased sensitivity of the major GH-signaling pathways in liver and skeletal muscle. Growth Horm IGF Res 2010; 20:118 - 26; http://dx.doi.org/10.1016/j.ghir.2009.11.003; PMID: 20022531
   PubMed Web of Science ®Google Scholar
• Haga S, Ozaki M, Inoue H, Okamoto Y, Ogawa W, Takeda K, et al. The survival pathways phosphatidylinositol-3 kinase (PI3-K)/phosphoinositide-dependent protein kinase 1 (PDK1)/Akt modulate liver regeneration through hepatocyte size rather than proliferation. Hepatology 2009; 49:204 - 14; http://dx.doi.org/10.1002/hep.22583; PMID: 19065678
   PubMed Web of Science ®Google Scholar
• Mullany LK, Nelsen CJ, Hanse EA, Goggin MM, Anttila CK, Peterson M, et al. Akt-mediated liver growth promotes induction of cyclin E through a novel translational mechanism and a p21-mediated cell cycle arrest. J Biol Chem 2007; 282:21244 - 52; http://dx.doi.org/10.1074/jbc.M702110200; PMID: 17517888
   PubMed Web of Science ®Google Scholar
• Friedbichler K, Themanns M, Mueller KM, Schlederer M, Kornfeld JW, Terracciano LM, et al. Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology 2012; 55:941 - 52; http://dx.doi.org/10.1002/hep.24765; PMID: 22031092
   PubMed Web of Science ®Google Scholar
• Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009; 15:513 - 20; http://dx.doi.org/10.3748/wjg.15.513; PMID: 19195051
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366:2 - 16; http://dx.doi.org/10.1016/j.gene.2005.10.018; PMID: 16377102
   PubMed Web of Science ®Google Scholar
• Xu X, Sakon M, Nagano H, Hiraoka N, Yamamoto H, Hayashi N, et al. Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol Rep 2004; 11:25 - 32; PMID: 14654898
   PubMed Web of Science ®Google Scholar
• Dahmani R, Just PA, Perret C. The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2011; 35:709 - 13; http://dx.doi.org/10.1016/j.clinre.2011.05.010; PMID: 21778132
   PubMed Web of Science ®Google Scholar
• Monga SP. Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol 2011; 43:1021 - 9; http://dx.doi.org/10.1016/j.biocel.2009.09.001; PMID: 19747566
   PubMed Web of Science ®Google Scholar
• Gotoh J, Obata M, Yoshie M, Kasai S, Ogawa K. Cyclin D1 over-expression correlates with beta-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3 beta and ERK1/2 in mouse hepatic carcinogenesis. Carcinogenesis 2003; 24:435 - 42; http://dx.doi.org/10.1093/carcin/24.3.435; PMID: 12663502
   PubMed Web of Science ®Google Scholar
• Ban KC, Singh H, Krishnan R, Seow HF. GSK-3beta phosphorylation and alteration of beta-catenin in hepatocellular carcinoma. Cancer Lett 2003; 199:201 - 8; http://dx.doi.org/10.1016/S0304-3835(03)00421-X; PMID: 12969793
   PubMed Web of Science ®Google Scholar
• Joo M, Kang YK, Kim MR, Lee HK, Jang JJ. Cyclin D1 overexpression in hepatocellular carcinoma. Liver 2001; 21:89 - 95; http://dx.doi.org/10.1034/j.1600-0676.2001.021002089.x; PMID: 11318977
   PubMedGoogle Scholar
• Nelsen CJ, Rickheim DG, Timchenko NA, Stanley MW, Albrecht JH. Transient expression of cyclin D1 is sufficient to promote hepatocyte replication and liver growth in vivo. Cancer Res 2001; 61:8564 - 8; PMID: 11731443
   PubMed Web of Science ®Google Scholar
• Nelsen CJ, Rickheim DG, Tucker MM, Hansen LK, Albrecht JH. Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes. J Biol Chem 2003; 278:3656 - 63; http://dx.doi.org/10.1074/jbc.M209374200; PMID: 12446670
   PubMed Web of Science ®Google Scholar
• Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci 2005; 1056:218 - 33; http://dx.doi.org/10.1196/annals.1352.026; PMID: 16387690
   PubMed Web of Science ®Google Scholar
• Lin CP, Liu CR, Lee CN, Chan TS, Liu HE. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol 2010; 2:16 - 20; PMID: 21160952
   PubMedGoogle Scholar
• Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, Bradon N, et al. Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol 2004; 2:e332; http://dx.doi.org/10.1371/journal.pbio.0020332; PMID: 15455033
   PubMed Web of Science ®Google Scholar
• Hartl M, Bader AG, Bister K. Molecular targets of the oncogenic transcription factor jun. Curr Cancer Drug Targets 2003; 3:41 - 55; http://dx.doi.org/10.2174/1568009033333781; PMID: 12570660
   PubMed Web of Science ®Google Scholar
• Behrens A, Sibilia M, David JP, Möhle-Steinlein U, Tronche F, Schütz G, et al. Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J 2002; 21:1782 - 90; http://dx.doi.org/10.1093/emboj/21.7.1782; PMID: 11927562
   PubMed Web of Science ®Google Scholar
• Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 2005; 41:2449 - 61; http://dx.doi.org/10.1016/j.ejca.2005.08.008; PMID: 16199154
   PubMed Web of Science ®Google Scholar
• Okamoto T, Sanda T, Asamitsu K. NF-kappa B signaling and carcinogenesis. Curr Pharm Des 2007; 13:447 - 62; http://dx.doi.org/10.2174/138161207780162944; PMID: 17348842
   PubMed Web of Science ®Google Scholar
• Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer 2012; 12:121 - 32; PMID: 22257950
   PubMed Web of Science ®Google Scholar
• Wullaert A, van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev 2007; 28:365 - 86; http://dx.doi.org/10.1210/er.2006-0031; PMID: 17431229
   PubMed Web of Science ®Google Scholar
• Jeay S, Sonenshein GE, Postel-Vinay MC, Kelly PA, Baixeras E. Growth hormone can act as a cytokine controlling survival and proliferation of immune cells: new insights into signaling pathways. Mol Cell Endocrinol 2002; 188:1 - 7; http://dx.doi.org/10.1016/S0303-7207(02)00014-X; PMID: 11911939
   PubMed Web of Science ®Google Scholar
• He G, Karin MNF. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011; 21:159 - 68; http://dx.doi.org/10.1038/cr.2010.183; PMID: 21187858
   PubMed Web of Science ®Google Scholar
• Abramovitch R, Tavor E, Jacob-Hirsch J, Zeira E, Amariglio N, Pappo O, et al. A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res 2004; 64:1338 - 46; http://dx.doi.org/10.1158/0008-5472.CAN-03-2089; PMID: 14973073
   PubMed Web of Science ®Google Scholar
• Chin KT, Zhou HJ, Wong CM, Lee JM, Chan CP, Qiang BQ, et al. The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma. Nucleic Acids Res 2005; 33:1859 - 73; http://dx.doi.org/10.1093/nar/gki332; PMID: 15800215
   PubMed Web of Science ®Google Scholar
• Mayo KE, Hammer RE, Swanson LW, Brinster RL, Rosenfeld MG, Evans RM. Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene. Mol Endocrinol 1988; 2:606 - 12; http://dx.doi.org/10.1210/mend-2-7-606; PMID: 3137455
   PubMed Web of Science ®Google Scholar
• Welinder C, Ekblad L. Coomassie staining as loading control in Western blot analysis. J Proteome Res 2011; 10:1416 - 9; http://dx.doi.org/10.1021/pr1011476; PMID: 21186791
   PubMed Web of Science ®Google Scholar
• Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156 - 9; http://dx.doi.org/10.1016/0003-2697(87)90021-2; PMID: 2440339
   PubMed Web of Science ®Google Scholar
• Masternak MM, Al-Regaiey KA, Del Rosario Lim MM, Bonkowski MS, Panici JA, Przybylski GK, et al. Caloric restriction results in decreased expression of peroxisome proliferators-activated receptors (PPARs) superfamily in muscle of normal and long-lived GHR-KO mice. J Gerontol A Biol Sci Med Sci 2005; 60:1238 - 45; http://dx.doi.org/10.1093/gerona/60.10.1238; PMID: 16282554
   PubMed Web of Science ®Google Scholar
• Wang Z, Masternak MM, Al-Regaiey KA, Bartke A. Adipocytokines and the regulation of lipid metabolism in growth hormone transgenic and calorie-restricted mice. Endocrinology 2007; 148:2845 - 53; http://dx.doi.org/10.1210/en.2006-1313; PMID: 17347312
   PubMed Web of Science ®Google Scholar